Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2018

Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Programmed Cell Death 1 Receptor

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 30099497
DOI: 10.1093/annonc/mdy312

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.PMID 30099497Read ↗

[Advances of heterogeneity of EGFR in non-small cell lung cancer].Semantic proximity Read ↗

Clonal morphology-guided combination therapies overcome heterogeneity-driven drug toleranceSemantic proximity Read ↗

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.Semantic proximity Read ↗

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancerSemantic proximity Read ↗

Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patientsSemantic proximity Read ↗

EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.Semantic proximity Read ↗

Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.Semantic proximity Read ↗

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.Semantic proximity Read ↗

Genetic dissection of intratumor heterogeneity of PD-L1 expression in EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.